RESA Encourages U.S. Energy Consumers to Shop on National Energy Shopping Day

HARRISBURG, Pa.--(BUSINESS WIRE)--The Retail Energy Supply Association (RESA), the national trade association representing competitive retail energy suppliers, is marking the sixth annual National Energy Shopping Day by encouraging Americans to take advantage of their power to choose.
Today is National Energy Shopping Day, which serves as an annual reminder to review your current energy plan, compare available offers, explore clean energy options and choose a gas and electric supplier that meets your individual needs.
Share
Recognized every year on the first day of summer and included in Chase's Calendar of Events, National Energy Shopping Day promotes consumer awareness and engagement in competitive energy markets. The day serves as a reminder for individuals and businesses in states with retail choice to shop for energy plans that reflect their personal preferences, whether that means seeking renewable options, locking in fixed rates or finding budget-friendly pricing.
'Shopping for energy is one of the most overlooked ways consumers can make a real impact on their energy bills, their sustainability goals and take control of their energy choices,' said Tracy McCormick, executive director of RESA. 'We believe that every consumer deserves more than one monopoly option. They deserve the right to choose.'
Currently, 14 states and the District of Columbia allow consumers to select their own electricity and/or natural gas supplier. However, a national survey by Ragnar Research Partners reveals a significant disconnect: 74% of Americans want to choose their energy provider, while only 28% currently have the option.
RESA offers free, easy-to-use tools at RESAusa.org to help consumers:
Determine if energy choice is available in their state
Where to compare energy providers and plans
How to shop for energy
Understand key contract terms and rate structures
Energy choice isn't just about shopping—it's about empowerment, competition and innovation. RESA remains committed to educating consumers, supporting transparent marketplaces and expanding access to energy choice nationwide.
ABOUT NATIONAL ENERGY SHOPPING DAY
National Energy Shopping Day is an initiative created by RESA to encourage individuals residing in states that offer retail energy choice in electric and natural gas suppliers to find the best provider tailored to their specific requirements. Consumers can select a plan that offers clean energy products or benefits, such as smart home integration or energy efficiency programs, for their homes or businesses. For more information, visit nationalenergyshoppingday.org
ABOUT RESA
The Retail Energy Supply Association is a broad and diverse group of retail energy suppliers who share the common vision that competitive retail electricity and natural gas markets deliver a more efficient, customer-oriented outcome than a regulated utility structure. RESA is devoted to working with all stakeholders to promote vibrant and sustainable competitive retail energy markets for residential and industrial consumers. For more information, visit resausa.org. Follow RESA on LinkedIn and X (Twitter).

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

16 minutes ago

• Business Wire

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, 'Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy,' from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. 'These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia,' said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. 'We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year.' 'It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events,' said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. 'As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future.' About Type 1 Diabetes T1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About Zimislecel Zimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website.

Miami Herald

an hour ago

• Miami Herald

Tony Robbins sends strong message to Americans on 401(k)s

Many Americans preparing for retirement through savings and investments often encounter significant financial hurdles as they work toward a secure and enjoyable future. They eventually come to realize that while Social Security provides a foundational stream of income, it was never designed to fully support every cost of living throughout the entirety of retirement. According to renowned motivational speaker and author Tony Robbins, although 401(k) plans offer valuable opportunities, workers frequently encounter scenarios that could jeopardize their long-term financial well-being. Don't miss the move: Subscribe to TheStreet's free daily newsletter Regularly contributing to retirement accounts that offer tax advantages - such as 401(k) plans and Individual Retirement Accounts (IRAs) - is a smart financial strategy. Taking full advantage of these contributions, particularly with regard to 401(k) plans when an employer match is available, can greatly enhance retirement savings over the long term. Robbins has emphasized the importance of financial awareness when it comes to retirement planning. One of his key messages is a warning to American workers regarding misconceptions about Social Security and 401(k) plans. Related: Jean Chatzky sends strong message to Americans on Social Security A crucial part of effective retirement planning certainly involves understanding how Social Security benefits are determined and carefully choosing when to begin claiming them. By postponing benefits beyond one's full retirement age, retirees can receive higher monthly payouts from the program. Considering this background, Robbins highlights a critical caution about how 401(k) plans are used - urging workers to avoid common pitfalls that could affect their financial futures. Tony Robbins points out that for three decades, companies managing 401(k) plans were not required to reveal how much they were charging in fees. Now that disclosure is mandatory, he believes many providers hide those costs in lengthy, complex documents - making it hard for individuals to truly grasp what they're paying and keeping them largely uninformed. "What the majority of Americans don't realize is that an increase in 1% in fees will cost you 10 years in retirement income," Robbins wrote. More on retirement: Dave Ramsey offers urgent thoughts about MedicareJean Chatzky shares major statement on Social SecurityTony Robbins has blunt words on IRAs,401(k)s Robbins uses a straightforward hypothetical scenario to underscore the long-term impact of investment fees on retirement savings. In his example, three employees - let's call them Employee 1, Employee 2, and Employee 3 - each invest $100,000 at age 35 into separate mutual funds. All three investments generate the same steady annual return of 8%, and none of them withdraw any funds for 30 years. However, each employee is subject to a different annual fee: 1%, 2%, and 3%, respectively. By the time they reach age 65, Robbins clarifies, the variation in fees has created a striking difference in their account balances. Despite identical contributions and returns, Employee 1, who paid the lowest fee, has nearly double the retirement savings of Employee 3, who paid the highest. Related: Dave Ramsey sends strong message to Americans on Medicare Robbins emphasizes that the cost of high investment fees doesn't end at retirement. Using the scenario of each employee needing $60,000 annually to fund their retirement, he notes that the long-term consequences become even clearer. The employee facing the highest fees - Employee 3 - depletes their savings before reaching 75, while Employee 1, who paid the lowest fees, sees their nest egg last until age 95. According to Robbins, this stark contrast demonstrates how even small differences in fees can compound into significant financial disparities. It's a powerful reminder, he says, that being mindful of investment costs isn't just a matter of saving money - it's a crucial step in safeguarding long-term financial security. "I learned about these abuses while writing 'Money: Master the Game,' and it made me so angry that people were getting robbed blind," Robbins wrote. "So I brought in America's Best 401(k)." America's Best 401(k) is a retirement plan provider that says it aims to reduce the high fees commonly associated with traditional 401(k) plans. Robbins asked the firm to asses the 401(k) plan used by his own research company and ended up using their proposed solution. "They showed me that we were paying 276% more than we needed to for the same exact stocks," Robbins wrote. "It saved my employees $5 million in their retirement, and it cost nothing." Related: Shark Tank's Kevin O'Leary warns Americans on 401(k)s The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Newsweek

2 hours ago

• Newsweek

Justice Jackson Warns of 'Reputational Cost' to Supreme Court After Ruling

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Supreme Court Justice Ketanji Brown Jackson criticized the majority's ruling in a case over fuel providers challenging the Environmental Protection Agency's (EPA) approval of California's vehicle emissions regulations, writing in a Friday dissent that the decision comes at a "reputational cost" for the court, according to documents reviewed by Newsweek. She added that the decision gives "fodder" to the perception that "moneyed interests, enjoy an easier road to relief in this Court than ordinary citizens." Why It Matters In a 7-2 decision, the Supreme Court reversed the D.C. Circuit and sided with fuel producers, ruling they have Article III standing to challenge the EPA's approval of California's vehicle emissions regulations. California's regulations "require automakers to limit average greenhouse-gas emissions across their vehicle fleets and manufacture a certain percentage of electric vehicles," the lawsuit reads. Several fuel producers sued the EPA over its approval of California's regulations, arguing the agency exceeded its authority under the Clean Air Act by approving regulations that target "global climate change rather than local California air quality problems." Jackson's dissent raised concerns about public perception of favoritism and the court being swayed by powerful interests. Confidence in the Supreme Court has steadily declined for decades, with 47 percent of Americans viewing the court favorably and 51 percent unfavorably, according to a 2024 Pew Research Center survey. In 1987, 76 percent held a favorable view, while just 17 percent viewed the court unfavorably. Supreme Court Justice Ketanji Brown Jackson at her Senate confirmation hearing on Capitol Hill on March 22, 2022. Supreme Court Justice Ketanji Brown Jackson at her Senate confirmation hearing on Capitol Hill on March 22, 2022. AP Photo/Carolyn Kaster What To Know In Diamond Alternative Energy v. Environmental Protection Agency, Justice Brett Kavanaugh issued the majority opinion, joined by Justice Elena Kagan, one of the court's liberals, holding that fuel producers have standing to challenge the EPA's approval of the California regulations. In her dissent, Jackson called out the majority's application of "standing doctrine," writing that "When courts adjust standing requirements to let certain litigants challenge the actions of the political branches but preclude suits by others with similar injuries, standing doctrine cannot perform its constraining function." She argued that "Over time, such selectivity begets judicial overreach and erodes public trust in the impartiality of judicial decision making." Jackson's dissent says the court is "setting us down that path." "I worry that the fuel industry's gain comes at a reputational cost for this Court, which is already viewed by many as being overly sympathetic to corporate interests," she said later in the opinion. Jackson argues that this perception, and even a mere "'appearance' of favoritism, founded or not," can undermine public confidence in the highest court. Justice Sonia Sotomayor also dissented, filing a separate opinion and not joining Jackson's. What People Are Saying Jonathan Adler, a professor at Case Western Reserve University School of Law, told NBC on Friday: "I don't think this case is an example of the court being inconsistent or somehow more favorable to moneyed interests than other sorts of interests. It's not like the court has closed the door on environmental groups." Supreme Court Justice Brett Kavanaugh wrote in the majority opinion: "Justice Jackson separately argues that the Court does not apply standing doctrine 'evenhandedly'...A review of standing cases over the last few years disproves that suggestion." Beth Milito, vice president of the National Federation of Independent Business' Small Business Legal Center, which filed an amicus brief in the case, said in a Friday press release: "Small businesses have the right to challenge overreach by government agencies and seek relief from harmful regulatory actions. The D.C. Circuit's opinion set an unreasonable standard for plaintiffs to prove that the court can remedy their injury. This would have made it nearly impossible for indirectly regulated parties to challenge regulating agencies. NFIB applauds the Court for reversing the lower court's opinion and ensuring that small businesses have a clear course of action and a fair chance at proving that the court can provide suitable relief." Kristen Waggoner, president and chief counsel of Alliance Defending Freedom, who filed an amicus brief in the case, said Friday on X (formerly Twitter): "The ruling in Diamond Alternative Energy v. EPA has significant implications beyond just environmental SCOTUS ruling will help plaintiffs, like these churches, hold the government accountable when its regulations have the downstream effect of violating their fundamental rights. An important win." What Happens Next The Supreme Court is expected to release a slew of opinions in the coming weeks, with the term scheduled to end in late June.